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ABSTRACT 
BACKGROUND:  Barnidipine is one of a new generation of dihydropyridine 
calcium-channel blockers. Despite evidence of favorable ffects on blood pressure (BP) 
and insulin sensitivity, this drug has rarely been tested in hypertensive patients with 
metabolic syndrome (MS). 
OBJECTIVE"  The aim of this study was to evaluate the effects of barnidipine on 
BP and left ventricular (LV) diastolic function in patients with hypertension a d MS. 
METHODS:  Consecutive subjects aged 18 to 75 years with systolic BP (SBP) of 
140 to 179 mm Hg and/or diastolic BP (DBP) of 90 to 109 mm Hg and MS (based on 
Adult Treatment Panel III criteria) were assessed for inclusion in the study. Lifestyle 
changes according to current guidelines were recommended and barnidipine mono- 
therapy 10 nag daily was initiated. All patients entered a 2-week run-in period. After 
a 6-week treatment period, the daily dosage was doubled for the remainder of the 
study in patients whose BP remained uncontrolled (->140/->90 mm Hg). We assessed 
the glycolipidic profile and LV structure and function using standard Doppler and tis- 
sue Doppler imaging (TDI) echocardiography before and after 12 weeks of treatment. 
Ambulatory BP records and electrocardiographic and echocardiographic tracings were 
coded and shipped to a central laboratory for blinded analysis. Possible adverse vents 
(AEs) were recorded at predetermined intervals throughout the follow-up period and at 
unplanned intervals whenever an AE became known to the investigators. 
RESULTS:  Thirty-four consecutive patients were assessed for inclusion. Thirty 
consecutive patients (20 men, 10 women; mean [SD] age, 55.9 [10.3] years; 5 current 
smokers) were included in the study. At study entry, mean office SBP was 146 mm Hg, 
DBP was 87 mm Hg, and heart rate was 72 beats/min. At the study end, mean office 
SBP/DBP was < 140/90 mm Hg in 20 patients (66.7%). From baseline to study end, 
24-hour ambulatory BP decreased significantly by 12 and 8 mm Hg for SBP and 
DBP, respectively (both, P = 0.001). The smoothness index was 0.92 for SBP and 
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0.82 for DBE Fasting plasma glucose concentration decreased significantly from 110 to 
104 mg/dL (P = 0.001). Total cholesterol, high-density lipoprotein cholesterol, and 
low-density lipoprotein cholesterol concentrations did not change significantly. From 
baseline to study end, there were no significant changes in LV structure or systolic 
function (LV mass, 50.7 vs 50.6 g/ht2v; LV diastolic/systolic diameters, 47.50/29.80 
vs 48.40/30.76 mm; wall motion score index, 1.0 vs 1.0; ejection fraction, 61% vs 
60%), while the peak E/A velocity ratio on TDI increased from 1.078 to 1.245 (P = 
0.009). No AEs (including AEs reflected by chemistry values) either unrelated or 
related to treatment were noted during the 12-week duration of the study. 
CONCLUSIONS:  In these hypertensive patients with MS, a 12-week treatment 
period with barnidipine in addition to lifestyle modifications was associated with 
significant reductions in 24-hour BP and BP variability, reduction in plasma glucose 
concentration, and improvement in LV diastolic relaxation. No significant changes in 
lipid concentrations, LV structure, or systolic function were found. (Curr Ther Res Clin 
Exp. 2008;69:207-220) © 2008 Excerpta Medica Inc. 
K~'YWORDS: barnidipine, hypertension, metabolic syndrome, left ventricular 
hypertrophy, diastolic dysfunction. 
INTRODUCTION 
Metabolic syndrome (MS), a constellation of risk factors of metabolic origin, is strongly 
associated with the development of type 2 diabetes and cardiovascular disease. 1,2 These 
factors may trigger a proinflammatory and prothrombotic state and identify individuals 
at elevated cardiovascular risk. 3-5 The main features of MS are an increased risk for fatal 
and nonfatal cardiovascular complications, a 3- to 6-fold higher isk of developing diabe- 
tes, a higher risk of new-onset hypertension, and a frequent association with subclinical 
organ damage (eg, microalbuminuria, arterial stiffening, left ventricular [LV] hypertro- 
phy, and diastolic dysfunction). 1,4 Tissue Doppler imaging (TDI), a relatively recent 
application of the Doppler principle, is increasingly used as a tool to investigate diastolic 
function. The TDI parameters ofdiastolic function are relatively unaffected by preload 
and heart rate (HR) and hence more valuable in distinguishing normal from abnormal 
and pseudonormal filling as compared with traditional Doppler parameters. 6-8 
The 2007 joint guidelines of the European Society of Hypertension and the 
European Society of Cardiology for the management of patients with hypertension 
included MS in the list of cardiovascular risk factors and decision criteria to estab- 
lish whether or not to begin drug treatment in hypertensive patients. 9 We searched 
MEDLINE for clinical studies which met all of the following pre-specified criteria: 
(1) effect of antihypertensive drugs in patients with MS; (2) publication before 
December 31, 2007 in peer-reviewed journals; (3) inclusion of patients with hyper- 
tension or high cardiovascular risk; and (4) measurement of blood pressure (BP) at 
baseline and follow-up. Although rigorous BP control is envisaged in patients with 
MS, 9,1° there is a paucity of intervention trials in hypertensive patients with MS. 1° 
The aim of this study was to investigate, in a sample of patients with mild to mod- 
erate hypertension with concomitant MS, the 24-hour antihypertensive effectiveness of 
208 
F. ANGEL I  ET  AL.  
barnidipine, .11-15 a third-generation calcium-channel blocker indicated for the treat- 
ment of hypertension. Similar to other dihydropyridine calcium antagonists, barnidi- 
pine has been reported to have a neutral tolerability profile with regard to insulin sensi- 
tivity, 15 indicating it might be particularly suitable for patients with MS, dyslipidemia, 
and impaired fasting glucose. 
PAT IENTS AND METHODS 
This 12-week, open-label, noncomparative study was carried out in patients attending 
our Clinic Research Unit of Preventive Cardiology in Perugia, Italy. Our institutional 
ethical committee approved the study (PROTOCOL DS/VAS/01) in March 2006, and 
all participants gave their written informed consent o participate in the study. 
We assessed patients aged 18 to 75 years with miM to moderate ssential hypertension 
(defined as systolic BP [SBP] of 140-179 mm Hg and/or diastolic BP [DBP] of 90- 
109 mm Hg) and a diagnosis of MS according to the Adult Treatment Panel III crite- 
ria. 1 All patients needed to meet predetermined inclusion and exclusion criteria. 
Female patients needed to be either postmenopausal for>1 year, surgically sterile, or 
using effective contraceptive methods. All patients required adiagnosis of hypertension 
and MS with ->3 of the following factors present: waist circumference >102 cm in men 
and >88 cm in women; triglycerides ->150 mg/dL; high-density lipoprotein cholesterol 
(HDL-C) <40 mg/dL in men and <50 mg/dL in women; BP ->130/->85 mm Hg; or fast- 
ing plasma glucose ->110 mg/dL. 
Patients were excluded for any of the following reasons: secondary form of hyper- 
tension; concomitant administration of BP-lowering drugs; Keith-Wagener grade III 
of IV 9 hypertensive r tinopathy; history of hypertensive encephalopathy or cerebro- 
vascular accident; transient ischemic cerebral attack; coronary bypass urgery or any 
percutaneous coronary intervention during the 6 months prior to the first study visit; 
present or past diagnosis of heart failure (New York Heart Association class II-IV); 
myocardial infarction, angina pecroris (treated with drugs different from oral or topical 
nitrates in stable doses); presence of potentially life-threatening arrhythmia or symp- 
tomatic arrhythmia; serum sodium <136 mEq/L, serum potassium <3.5 mEq/L or 
>5.5 mEq/L; major gastrointestinal tract surgery (eg, gastrectomy, gastroenterostomy, 
bowel resection); active or previously active inflammatory bowel disease during the 
12 months prior to the first study visit; active gastritis, duodenal or gastric ulcers, or 
gastrointestinal/rectal bleeding during the 3 months prior to the first study visit; his- 
tory of pancreatic injury or pancreatitis or evidence of impaired pancreatic function/ 
injury, as indicated by abnormal lipase or amylase activity; evidence of hepatic injury, 
as determined by either of the following--aspartate aminotransferase or alanine ami- 
notransferase activity >3 times the upper limit of normal at the first study visit or a 
history of hepatic encephalopathy, esophageal varices, or portocaval shunt; evidence 
of renal impairment, as determined by any one of the following--serum creatinine 
>1.7 mg/dL for women and >2.0 mg/dL for men at first visit or history of dialysis 
or nephrotic syndrome; history or evidence of drug or alcohol abuse within the last 
*Trademark: Vasexten ®(Italfarmaco, S.p.A., Cinisello Balsamo, Milan, Italy). 
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12 months; pregnancy or breastfeeding; any surgical or medical condition that, in the 
opinion of the investigator, might place the patient at increased risk from his/her par- 
ticipation in the study or was likely to prevent he patient from complying with the 
requirements of the study or completing the study; concomitant treatment with drugs 
potentially interfering with barnidipine (eg, antiprotease drugs, ketoconazole, itracona- 
zole, erythromycin, clarithromycin); history of noncompliance to medical regimens or 
unwillingness to comply with the study protocol; or participation in any investigational 
drug trial within 1 month of the first study visit. 
All patients were initially advised to make lifestyle modifications, where appropri- 
ate, according to current guidelines. 9 After a 2-week run-in period during which previ- 
ous antihypertensive drugs were discontinued, patients entered the active phase of the 
study, which lasted 12 weeks. Diuretics and 13-blockers were discontinued because they 
are associated with increased risk of developing diabetes) 6 Barnidipine monotherapy 
was administered between 7:00 AM and 9:00 PM at the initial daily dose of 10 mg. 
The dosage was doubled to 20 nag daily in those patients whose hypertension remained 
uncontrolled (SBP _>140 mm Hg and/or DBP ->90 mm Hg) at the end of 6 weeks 
of treatment. All other drugs that did not affect BP were not changed during the 
study. 
BP was measured by the same physician for all patients with a standard mercury 
sphygmomanometer in a quiet, comfortable room with temperature verified to be in 
the range of 18°C to 27°C. Patients were seated and relaxed for _>10 minutes before BP 
was measured on the nondominant arm. 
HR was obtained from the radial artery. The means of 3 consecutive measurements 
were used for the statistical analysis of both BP and HR. 
All laboratory testing (creatinine, potassium, plasma glucose, total cholesterol, 
HDL-C, low-density lipoprotein cholesterol [LDL-C], triglycerides) was carried out 
after an overnight fast at the beginning of the study and after 12 weeks of treatment. 
Ambulatory BP was recorded using an oscillometric device (SpaceLabs 90207, 
SpaceLabs, Redmond, Washington) set to take a reading every 15 minutes throughout 
the 24-hour monitoring period. Ambulatory BP monitoring was performed at the begin- 
ning of the study and after 12 weeks of treatment. Mean 24-hour, daytime (6:00 AM-- 
10:00 PM), and nighttime (10:00 PM--6:00 AM) BP were determined. BP variability 
was estimated using the SD of daytime and nighttime SBP and DBP. The smooth- 
ness index was computed to analyze the stability of BP reduction over the 24-hour 
monitoring period. 17 
A standard 12-lead electrocardiogram (ECG) was recorded in all patients at 25 mm/s 
and 1 mV/cm calibration. LV hypertrophy was diagnosed using a prognostically vali- 
dated score 18 developed in our laboratory, 19 which requires positivity of _>1 of the fol- 
lowing 3 criteria: (1) modified Cornell voltage (ECG amplitude SV 3 + RaVL >2.4 mV 
in men, >2.0 mV in women); (2) typical LV strain (inverted T wave with asymmetric 
branches associated with a flat or down-sloping ST segment, with _>0.05 mV depression 
80 ms after the J poin0; and (3) a Romhilt-Estes point score of->5.19 
LV structure and systolic function were evaluated by standard 2D-guided M-Mode 
echocardiography. Only frames with optimal visualization of interfaces and show- 
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ing simultaneous visualization of septum, LV internal diameter, and posterior wall 
were used for reading. LV mass was calculated using a standard formula validated 
by Devereux et al 2° and corrected by height in meters at the power of 2.7 in order to 
correct for overweight and obesity. 21 LV hypertrophy was defined by an LV mass 
>51.0 g/(height in meters)2.7. 21 Diastolic function was evaluated through standard Doppler 
imaging (peak E area, peak A area, peak E/A area ratio, E velocity, A velocity, E/A ve- 
locity ratio) and TDI. 6,7 TDI targeted to the lateral mitral valve anulus was used to 
analyze early and late diastolic anular motion (E a and A ,  respectively). 6,7
All 24-hour ambulatory BP records, ECG, and echocardiographic tracings were 
coded and shipped to a central laboratory for analysis. Readers were unaware of the 
clinical characteristics of the patients or their treatment. 
Possible adverse vents (AEs) were recorded at predetermined intervals throughout 
the follow-up period and at unplanned intervals whenever an AE became known to an 
investigator. 
STAT IST ICAL  ANALYS IS  
Statistical analysis was performed using SPSS version 14 (SPSS Inc., Chicago, Illinois) 
and STATA version 8 (StataCorp LP, College Station, Texas). Parametric data were 
reported as mean (SD). Comparisons between pretreatment and treatment values were 
made using the t test for paired samples (continuous variables) and the ~2 test (categori- 
cal variables) when applicable. A 2-sided ot of 0.05 was used; therefore, P < 0.05 was 
considered statistically significant. 
RESULTS 
Of 34 hypertensive patients screened, 4 did not meet the inclusion criteria and were 
excluded from the study. The remaining 30 patients (20 men, 10 women; mean [SD] 
age, 55.9 [10.3] years; 5 current smokers), 15 of whom had never been treated for hyper- 
tension, were included in the study (Table I). All 30 patients completed the study. 
At study entry (visit 1), mean (SD) office SBP was 146 (10) mm Hg, DBP was 
87 (11) mm Hg, and HR was 72 (10) beats/rain. At the end of the 2-week run-in period 
(visit 2, baseline), SBP was 153 (6) mm Hg, DBP was 92 (5) mm Hg, and HR was 
74 (8) beats/rain (Table II). Ten patients (33.3%) received lipid-lowering drugs during 
the study. At entry, none of the study patients were being treated with insulin or 
glucose-lowering drugs. During the study, no changes in glucose or lipid-lowering 
drugs were prescribed. At baseline, 14 patients (46.7%) had impaired fasting plasma 
glucose (_>100 mg/dL) and 3 (10.0%) had diabetes mellitus. 
EFFECT OF BARNID IP INE  ON BLOOD PRESSURE 
The changes in office BP during the study are reported in Table II and Figure 1. At 
week 6 (visit 3), 12 patients (40.0%) had not achieved adequate BP control and, there- 
fore, their daily dosage of barnidipine was doubled to 20 rag. At week 12 (visit 4), mean 
office BP was <140/90 mm Hg in 20 patients (66.7%). Mean SBP and DBP decreased 
significantly from baseline (-22 and -12 mm Hg, respectively; both, P = 0.001). Mean 
HR did not change significantly during the course of the study. 
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Table I, Baseline demographic and clinical characteristics of patients with 
hypertension and metabolic syndrome (N = 30).* 
Characteristic Value 
Age, mean (SD), y 55.9 (10.3) 
Sex, no. (%) 
Male 
Female 
BSA, mean (SD), m 2 
Current smoker, no. (%) 
History of dyslipidemia, no. (%) 
Antihypertensive treatment at baseline, no. (%) 
20 (66.7) 
10 (33.3) 
1.99 (0.19) 
5 (16.7) 
10 (33.3) 
15 (50.0) 
BSA = body surface area. 
*No significant between-group differences were found. 
Table II. Effects of treatment with barnidipine on office blood pressure and laboratory 
findings in patients with hypertension and metabolic syndrome treated with 
bamidipine once daily (N = 30). Data are mean (SD) unless otherwise indicated. 
Visit 1 Visit 2 Visit 3 Visit 4 
Variable (Week -2) (Week O) (Week 6) (Week 12) P* 
Office monitoring 
SBP, mm Hg 146 (10) 153 (6) 127 (11) 131 (9) 0.001 
DBP, mm Hg 87 (11) 92 (5) 81 (8) 80 (10) 0.001 
HR, beats/rain 72 (10) 74 (8) 70 (9) 69 (8) 0.084 
Laboratory findings 
Creatinine, mg/dL - 1.05 (0.13) - 1.05 (0.13) 0.98 
Plasma glucose, mg/dL - 110 (24) - 104 (26) 0.001 
IFG, no. (%)t - 17 (56.7) - 16 (53.3) 0.80 
Total cholesterol, mg/dL - 202 (30) - 202 (32) 0.99 
HDL cholesterol, mg/dL - 53 (13) - 56 (12) 0.19 
LDL cholesterol, mg/dL - 112 (31) - 114 (27) 0.60 
Triglycerides, mg/dL - 176 (98) - 168 (104) 0.66 
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; IFG = impaired fasting 
glucose; HDL = high-density lipoprotein; LDL = low-density lipoprotein. 
*Week 12 versus week O. 
tSerum glucose concentration >100 mg/dL. 
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Figure 1. Changes in office systolic and diastolic blood pressure (SBP and DBP) and 
heart rate (HR) after 12 weeks of treatment with barnidipine (10-20 mg QD) in 
patients with hypertension and metabolic syndrome (N : 30). Treatment was 
started at visit 2 after a run-in period of 2 weeks. *P : 0.001 versus baseline. 
From baseline to study end, 24-hour ambulatory SBP and DBP decreased signifi- 
cantly (-12 and -8 mm Hg, respectively; both, P = 0.001), while ambulatory HR did 
not change significantly (Table III and Figure 2). 
Mean (SD) SBP variability decreased significantly from 13 (3) mm Hg to 11 (3) mm Hg 
(P = 0.043) during the daytime and from 12 (3) mm Hg to 10 (3) mm Hg (P = 0.040) 
during the nighttime. DBP variability did not change significantly. The smoothness 
index was 0.82 for ambulatory SBP and 0.92 for ambulatory DBP. 
METABOLIC PARAMETERS 
From baseline to week 12, there were no significant changes in total cholesterol 
(202 [30] vs 202 [32] mg/dL, respectively), HDL-C (53 [13] vs 56 [12] mg/dL), LDL-C 
(112 [31] vs 114 [27] mg/dL), or triglycerides (176 [98] vs 168 [104] mg/dL). Mean fast- 
ing plasma glucose concentration decreased 6 mg/dL from baseline (110 [24] vs 104 [26]; 
P = 0.001) (Table II). 
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Table III. Effects of treatment with barnidipine on 24-hour ambulatory blood pressure in 
patients with hypertension and metabolic syndrome (N : 30). Data are mean 
(SD). 
Visit 2 Visit 4 
Variable (Week O) (Week 12) P 
24-Hour monitoring 
SBP, mm Hg 134 (10) 122 (10) 0.001 
DBP, mm Hg 85 (8) 77 (7) 0.001 
HR, beats/min 70 (10) 73 (9) 0.25 
Daytime (6 AM-8 PM) monitoring 
SBP, mm Hg 139 (10) 126 (9) 0.001 
DBP, mm Hg 90 (8) 81 (7) 0.001 
HR, beats/min 73 (11) 75 (11) 0.24 
Nighttime BP (8 PM-6 AM) monitoring 
SBP, mm Hg 123 (12) 114 (13) 0.001 
DBP, mm Hg 74 (10) 69 (10) 0.017 
HR, beats/min 65 (9) 67 (10) 0.22 
BP variability 
Daytime SBP, mm Hg 13 (3) 11 (3) 0.043 
Daytime DBP, mm Hg 11 (2) 10 (3) 0.25 
Nighttime SBP, mm Hg 12 (3) 10 (3) 0.040 
Nighttime DBP, mm Hg 10 (2) 9 (4) 0.72 
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate. 
LEFT  VENTRICULAR STRUCTURE AND FUNCTION 
At baseline, LV hypertrophy was detected by standard ECG in 4 patients (13.3%). 
There were no significant changes in any of the ECG parameters of LV hypertrophy 
at the end of the study. Similarly, there were no significant changes in LV structure 
or systolic function, as detected by standard 2D-guided M-Mode echocardiography. 
No significant changes were found in the ejection fraction, left atrial diameter, or LV 
diameters (Table IV). 
The mean (SD) Ea/A a ratio on TDI increased significantly from 1.078 (0.328) at base- 
line to 1.245 (0.231) at week 12 (P = 0.009), while no significant changes were found 
with standard transmitral Doppler flow parameters (peak E velocity, peak A velocity 
and their ratio) (Figure 3). 
TOLERABIL ITY  
No AEs (including AEs reflected by chemistry values) either unrelated or related to 
treatment were noted during the 12-week duration of the study. In particular, there 
were no cases of ankle edema. 
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Table IV. Changes in electrocardiographic (ECG) and echocardiographic parameters after 
12 weeks of treatment with barnidipine in patients with hypertension and meta- 
bolic syndrome (N = 30). Data are mean (SD) unless otherwise indicated. 
Visit 2 Visit 4 
Variable (Week O) (Week 12) P 
ECG 
LV hypertrophy-Cornell/strain, o. (%) 4 (13.3) 4 (13.3) 0.99 
Cornell voltage, mV 15.5 (7.2) 15.8 (8.4) 0.70 
Sokolow-Lyon voltage, mV 19.2 (5.9) 19.1 (6.2) 0.82 
Typical strain, % 3.3 3.3 0.90 
Echocardiography 
LVM, g/ht 2.7 50.7 (12.6) 50.6 (13.8) 0.88 
LVM/ht 2"7 >51, no. (%) 15 (50.0) 12 (40.0) 0.06 
Left atrial diameter, mm 36.8 (5.2) 36.6 (4.7) 0.53 
LV systolic diameter, mm 29.80 (4.65) 30.76 (4.23) 0.12 
LV diastolic diameter, mm 47.50 (5.12) 48.40 (5.41) 0.10 
LV systolic function 
WMSl 1.0 1.0 0.99 
Ejection fraction, % 61 (10) 60 (8) 0.50 
LV diastolic function by standard PD 
Peak E velocity, m/s 0.59 (0.11) 0.60 (0.10) 0.37 
Peak A velocity, m/s 0.67 (0.11) 0.66 (0.14) 0.72 
Peak E velocity/Peak A velocity ratio 0.91 (0.28) 0.95 (0.23) 0.24 
LV diastolic function by TDI 
Peak E velocity, m/s 0.092 (0.023) 0.091 (0.014) 0.71 
Peak A velocity, m/s 0.090 (0.024) 0.076 (0.020) 0.001 
Peak E velocity/Peak A velocity ratio 1.078 (0.328) 1.245 (0.231) 0.009 
LV = left ventricular; LVM = left ventricular mass; WMSI = wall motion score index; PD = pulsed Doppler; 
TDI = tissue Doppler imaging. 
DISCUSSION 
The present study suggests that a 12-week treatment period with barnidipine 10- 
20 mg daily provided a consistent 24-hour BP-lowering effect in these patients with 
hypertension and concomitant MS. Office BP normalization was achieved in 66.7% of 
patients, and 24-hour ambulatory SBP/DBP decreased by 12/8 mm Hg. BP control was 
sustained and constant over the 24-hour monitoring period, as suggested by the 
smoothness indexes 17 of 0.82 and 0.92 for SBP and DBP, respectively, and the signifi- 
cant reduction in daytime and nighttime BP variability. There were significant 
improvements in LV relaxation, as assessed by TDI, and a small but significant reduc- 
tion in plasma glucose concentration from baseline. 
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Figure 3. Effect of treatment with barnidipine (10-20 mg QD) on diastolic function 
evaluated using tissue Doppler imaging echocardiography. Early and late 
diastolic anular motion (Ea/Aa) ratio before and after 12 weeks of treatment 
are reported with SD. *P = 0.009. 
DRUG TREATMENT OF  HYPERTENSIVE  PAT IENTS WITH METABOLIC  SYNDROME 
The growing importance of MS in the decision-making process in patients with 
essential hypertension was recognized in the 2007 joint guidelines of the European 
Society of Hypertension and the European Society of Cardiology. 9 The document sug- 
gests that MS, even in the absence of other risk factors, is a reason to begin drug treat- 
ment in hypertensive patients with stage 1 hypertension. Even in patients with high- 
normal BP (SBP 130-139 mm Hg or DBP 95-99 mm Hg), MS is identified as a reason 
to consider drug treatment. The same document states that diuretics and B-blockers 
should be avoided in hypertensive patients at high risk of developing diabetes mellitus, 
such as those with MS. 
The present study, specifically designed for hypertensive patients with MS, may 
provide further insights into the management of these patients. Barnidipine admin- 
istered once daily was associated with significant, sustained 24-hour BP control. The 
importance of achieving adequate 24-hour BP control is supported by the large body 
of evidence that supports the strong prognostic value of ambulatory BP 6,22 and by the 
evidence that in-treatment ambulatory BP levels are superior to pretreatment levels 
in identifying patients at increased cardiovascular risk. 23 At any level of ambulatory 
BP, lesser BP variability during the day and night is also associated with a lesser isk 
of future cardiovascular disease. 24,25 In this context, it is noteworthy that barnidipine 
treatment was associated with a significant reduction in BP variability in the present 
study. 
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METABOLIC  EFFECTS 
There was a small, albeit statistically significant, reduction in plasma glucose 
concentration and no significant effects on lipid concentrations. These results 
are consistent with a previous study by Kosegawa et al, 15 who noted improve- 
ment in insulin sensitivity (increased glucose infusion rate from 3.91 [0.43] to 5.29 
[0.43] mg/kg • min-1; P = 0.028) after barnidipine administration in hypertensive 
patients. Improved blood flow to pancreatic islets resulting from arteriolar vasodilata- 
tion might have been one mechanism of improved insulin sensitivity. 1~ 
CARDIAC EFFECTS 
There were no significant effects on the ECG markers of LV hypertrophy or the 
echocardiographic indexes of LV structure. It is likely that the duration of the study 
and the inclusion criteria, which were not based on LV hypertrophy, precluded iden- 
tifying detectable ffects on hypertrophy regression. However, we noted for the first 
time a significant improvement in the TDI parameters of diastolic function (peak E 
velocity/peak A velocity) during treatment. In several clinical conditions, including 
hypertension, heart failure, and acute myocardial infarction, LV diastolic dysfunction 
detected by TDI predicted major cardiovascular events and mortality. 26 
The main limitation of this study is inherent in its open-label and noncomparative 
design. To partially overcome this limitation, great care was taken to ensure a central 
blind assessment of the main outcome measures, including ECG, echocardiography, 
and 24-hour ambulatory BP. Further large, blinded, controlled studies are needed to 
confirm these effects of barnidipine on LV diastolic functions and metabolic profile. 
No sample size calculation was done, either a priori or post hoc protocol. 
CONCLUSIONS 
We found that lifestyle modifications and a 12-week treatment period with barnidipine 
monotherapy according to current guidelines in these hypertensive patients with MS 
were associated with a significant reduction in 24-hour BP and BP variability, with 
concomitant reduction in plasma glucose concentration and improvement in LV dia- 
stolic relaxation. No significant changes in lipid concentrations, LV structure, or systolic 
function were observed. 
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